Active substances
Amlodipine + Atorvastatin
- SFDA 12
- US FDA 7
- Health Canada 24
- US price lines 11
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CADUET 10-10 | 10,10 mg,mg | Tablet · Oral use | 30 Blister | SAR 111.25 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CADUET 10-20 | 20,10 mg,mg | Tablet · Oral use | 30 Blister | SAR 111.25 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CADUET 10-40 | 40,10 mg,mg | Tablet · Oral use | 30 Blister | SAR 154.60 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CADUET 5-10 | 10,5 mg,mg | Tablet · Oral use | 30 Blister | SAR 107.30 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CADUET 5-20 | 20,5 mg,mg | Tablet · Oral use | 30 Blister | SAR 107.30 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CADUET 5-40 | 40,5 mg,mg | Tablet · Oral use | 30 Blister | SAR 150.75 | NCE · Prescription | Viatris Arabia Limited | Valid |
| CODRIL 10/10 mg film-coated tablet | 10, 10 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 142.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CODRIL 10/5 mg film-coated tablet | 10, 5 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 143.50 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CODRIL 20/10 mg film-coated tablet | 20, 10 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 198.60 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CODRIL 20/5 mg film-coated tablet | 20, 5 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 199.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CODRIL 40/10 mg film-coated tablet | 40, 10 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 210.95 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| CODRIL 40/5 mg film-coated tablet | 40, 5 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 211.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CORONARY ARTERY DISEASE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CADUET | EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE; EQ 2.5MG BASE;EQ 10MG BASE; EQ 2.5MG BASE;EQ 20MG BASE; EQ 2.5MG BASE;EQ 40MG BASE | tablet · oral | PHARMACIA | Prescription | 30 Jan 2004 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE | tablet · oral | MYLAN | Prescription | 29 Nov 2013 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 2.5MG BASE;EQ 10MG BASE; EQ 2.5MG BASE;EQ 20MG BASE; EQ 2.5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE | tablet · oral | DR REDDYS | Prescription | 7 Mar 2014 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 2.5MG BASE;EQ 10MG BASE; EQ 2.5MG BASE;EQ 20MG BASE; EQ 2.5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE | tablet · oral | NEOCUBES PHARMA | Prescription | 11 Jan 2019 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE | tablet · oral | APOTEX | Prescription | 18 Nov 2019 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 2.5MG BASE;EQ 10MG BASE; EQ 2.5MG BASE;EQ 20MG BASE; EQ 2.5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 10MG BASE; EQ 5MG BASE;EQ 20MG BASE; EQ 5MG BASE;EQ 40MG BASE; EQ 5MG BASE;EQ 80MG BASE; EQ 10MG BASE;EQ 10MG BASE; EQ 10MG BASE;EQ 20MG BASE; EQ 10MG BASE;EQ 40MG BASE; EQ 10MG BASE;EQ 80MG BASE | tablet · oral | ALEMBIC | Prescription | 22 May 2025 |
| AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM | EQ 2.5MG BASE;EQ 10MG BASE; EQ 2.5MG BASE;EQ 20MG BASE; EQ 2.5MG BASE;EQ 40MG BASE | tablet · oral | MYLAN | Discontinued | 29 Nov 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-AMLODIPINE-ATORVASTATIN | 02411253 | 10 MG; 5 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411261 | 20 MG; 5 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411288 | 40 MG; 5 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411296 | 5 MG; 80 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411318 | 10 MG; 10 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411326 | 20 MG; 10 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411334 | 40 MG; 10 MG | TABLET · ORAL | APOTEX INC |
| APO-AMLODIPINE-ATORVASTATIN | 02411342 | 80 MG; 10 MG | TABLET · ORAL | APOTEX INC |
| CADUET | 02273233 | 10 MG; 5 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273241 | 5 MG; 20 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273268 | 5 MG; 40 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273276 | 5 MG; 80 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273284 | 10 MG; 10 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273292 | 20 MG; 10 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273306 | 10 MG; 40 MG | TABLET · ORAL | BGP PHARMA ULC |
| CADUET | 02273314 | 80 MG; 10 MG | TABLET · ORAL | BGP PHARMA ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362759 | 10 MG; 5 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362767 | 5 MG; 20 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362775 | 40 MG; 5 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362783 | 80 MG; 5 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362791 | 10 MG; 10 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362805 | 10 MG; 20 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362813 | 40 MG; 10 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-AMLODIPINE/ATORVASTATIN | 02362821 | 80 MG; 10 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMLODIPINE-ATORVAST 10-10 MG | $0.97947 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 10-20 MG | $0.79702 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 10-40 MG | $1.33627 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 10-80 MG | $1.56509 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 2.5-10 MG | $3.07993 | per EA | 19 Aug 2026 |
| US NADAC | AMLODIPINE-ATORVAST 2.5-20 MG | $4.49673 | per EA | 22 Apr 2026 |
| US NADAC | AMLODIPINE-ATORVAST 2.5-40 MG | $5.0363 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 5-10 MG | $1.08105 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 5-20 MG | $0.88094 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 5-40 MG | $1.19146 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-ATORVAST 5-80 MG | $1.55758 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.